Beginning in January 2003 all manufacturer clinical submissions (AMCP format-based dossier) must be in an electronic format and sent to the following electronic mail address: PDL@fssa.in.gov. Please note, submissions deviating from these guidelines will not be considered. Paper copies will not be accepted and should not be mailed to any of the involved parties including OMPP, ACS, a Xerox Company, or the T Committee members. All supplemental rebate bid submissions must be sent to ACS via SLFT (https://dit.acs-inc.com).

Senate Bill 228 establishes a Therapeutics subcommittee (T Committee) of the DUR Board charged with developing a Preferred Drug List effective September 2002.

7 Members consisting of:
5 Physicians
2 Pharmacists

Therapeutics Committee Membership Directory

In accordance with Indiana law, the entire preferred drug list must be reviewed twice each year. Semiannual reviews will occur in the months of February and August.

The review will include:
        Current Therapeutic Class Review
        Information submitted by manufacturers
        TCR Change document
          (detailing any changes to drugs or utilization since last review)

Semiannual PDL Review Schedule

Open Door Policy
Senate Bill 228

PDL@fssa.in.gov

Please submit all manufacturer contact information using the Supplemental Rebate Contact Form. All contact information should be submitted to PDL@fssa.in.gov

Please review the timelines provided on the meeting schedule page for the deadlines for electronic submission.

Meeting 1:	Open session to discuss clinical aspects of drugs The time remaining at the end of Meeting 1 will be allocated for public comment. Comment will be limited to two speakers per product and two minutes per speaker. Speakers may only present new product information (changes since the last review) or new products. There will only be one sign-in sheet for speakers. There will not be a sign-in sheet for each class. The sign-in sheet will be available the morning of the meeting. The committee will accept all written communications: public comment in the form of letters, speaker handouts and pharmaceutical manufacturer information, etc. via the pdl@fssa.in.gov email address.
Meeting 2:	Closed executive session to discuss confidential or proprietary information.
Meeting 3:	Open session to recommend preferred drug(s) to the upcoming DUR Board.

After considering therapeutic class review documentation, manufacturer submissions, and public comment, the Therapeutics Committee makes PDL recommendations to the DUR Board.

OBRA '90 Overview

Federal Regulations

Indiana Open Door Policy

Senate Bill 228